Ifm Investors Pty LTD Vertex Pharmaceuticals Inc Transaction History

Ifm Investors Pty LTD

$10.3 Billion
Q3 2024

A detailed history of Ifm Investors Pty LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ifm Investors Pty LTD holds 53,422 shares of VRTX stock, worth $26.8 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

53,422

Previous 53,487 0.12%

Holding current value

$26.8 Million

Previous $25.1 Million 0.9%

% of portfolio

0.24%

Previous 0.26%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$460.0 - $505.78 $29,900 - $32,875	-65 Reduced 0.12%	53,422 $24.8 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $406,165 - $502,038	1,034 Added 1.97%	53,487 $25.1 Million
Q1 2024 Apr 22, 2024	SELL	$407.69 - $446.08 $86,837 - $95,015	-213 Reduced 0.4%	52,453 $21.9 Million
Q4 2023 Jan 12, 2024	SELL	$343.0 - $410.68 $95,011 - $113,758	-277 Reduced 0.52%	52,666 $21.4 Million
Q3 2023 Oct 26, 2023	BUY	$338.18 - $362.46 $575,920 - $617,269	1,703 Added 3.32%	52,943 $18.4 Million
Q2 2023 Jul 27, 2023	BUY	$314.42 - $351.91 $1.29 Million - $1.44 Million	4,102 Added 8.7%	51,240 $18 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $403,036 - $459,771	1,423 Added 3.11%	47,138 $14.9 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $338,339 - $380,632	1,184 Added 2.66%	45,715 $13.2 Million
Q3 2022 Oct 12, 2022	BUY	$273.83 - $305.53 $164,571 - $183,623	601 Added 1.37%	44,531 $12.9 Million
Q2 2022 Jul 15, 2022	BUY	$234.96 - $292.55 $516,677 - $643,317	2,199 Added 5.27%	43,930 $12.4 Million
Q1 2022 Apr 13, 2022	BUY	$221.42 - $260.97 $1.67 Million - $1.97 Million	7,534 Added 22.03%	41,731 $10.9 Million
Q4 2021 Jan 18, 2022	SELL	$177.01 - $223.45 $71,335 - $90,050	-403 Reduced 1.16%	34,197 $7.51 Million
Q3 2021 Oct 13, 2021	BUY	$181.39 - $202.99 $362 - $405	2 Added 0.01%	34,600 $6.28 Million
Q2 2021 Jul 16, 2021	BUY	$187.49 - $221.1 $1.08 Million - $1.28 Million	5,776 Added 20.04%	34,598 $6.98 Million
Q1 2021 May 05, 2021	BUY	$207.02 - $241.31 $796,612 - $928,560	3,848 Added 15.41%	28,822 $6.19 Million
Q4 2020 Jan 13, 2021	BUY	$207.01 - $276.09 $620,408 - $827,441	2,997 Added 13.64%	24,974 $5.9 Million
Q3 2020 Oct 16, 2020	BUY	$255.65 - $303.1 $790,725 - $937,488	3,093 Added 16.38%	21,977 $5.98 Million
Q2 2020 Jul 13, 2020	SELL	$225.48 - $295.8 $1.49 Million - $1.95 Million	-6,591 Reduced 25.87%	18,884 $5.48 Million
Q1 2020 Apr 09, 2020	SELL	$199.77 - $247.81 $188,383 - $233,684	-943 Reduced 3.57%	25,475 $5.91 Million
Q4 2019 Jan 13, 2020	SELL	$166.71 - $223.91 $196,384 - $263,765	-1,178 Reduced 4.27%	26,418 $5.78 Million
Q3 2019 Nov 01, 2019	BUY	$166.23 - $187.09 $1.58 Million - $1.78 Million	9,502 Added 52.51%	27,596 $4.68 Million
Q2 2019 Jul 16, 2019	BUY	$164.61 - $190.37 $202,305 - $233,964	1,229 Added 7.29%	18,094 $3.32 Million
Q1 2019 Apr 18, 2019	BUY	$163.73 - $194.7 $356,931 - $424,446	2,180 Added 14.85%	16,865 $3.1 Million
Q4 2018 Jan 23, 2019	BUY	$151.91 - $192.21 $202,040 - $255,639	1,330 Added 9.96%	14,685 $2.43 Million
Q3 2018 Oct 22, 2018	BUY	$167.73 - $192.74 $327,744 - $376,613	1,954 Added 17.14%	13,355 $2.57 Million
Q2 2018 Jul 09, 2018	BUY	$145.72 - $169.96 $513,663 - $599,109	3,525 Added 44.76%	11,401 $1.94 Million
Q1 2018 May 11, 2018	BUY	$151.6 - $177.13 $126,282 - $147,549	833 Added 11.83%	7,876 $1.28 Million
Q4 2017 Jan 29, 2018	BUY	$137.28 - $155.55 $5,765 - $6,533	42 Added 0.6%	7,043 $1.06 Million
Q3 2017 Nov 16, 2017	BUY	$148.13 - $162.24 $29,774 - $32,610	201 Added 2.96%	7,001 $1.06 Million
Q2 2017 Nov 21, 2017	BUY	N/A	6,800 New	6,800 $876,000
Q2 2017 Aug 10, 2017	SELL	N/A	-4,989 Closed	0 $0
Q1 2017 Nov 21, 2017	BUY	N/A	4,989	4,989 $546,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ifm Investors Pty LTD with notifications on news.

Account

Ifm Investors Pty LTD Vertex Pharmaceuticals Inc Transaction History